DNA Medicine Focused INOVIO Pharma Efficiencies Implemented By Leadership Will Help De-Risk Its Platform Technology: Analyst
DNA Medicine Focused INOVIO Pharma Efficiencies Implemented By Leadership Will Help De-Risk Its Platform Technology: Analyst
Stephens initiated coverage on INOVIO Pharmaceuticals Inc (NASDAQ:INO), noting the company's diversified clinical pipeline of therapeutic and vaccine candidates, which the company is looking to advance eight additional clinical-stage candidates.
斯蒂芬斯開始對INOVIO Pharmicals Inc（納斯達克股票代碼：INO）進行報道，指出該公司擁有多元化的治療和疫苗候選臨床產品線，該公司正在尋求再推出八種臨床階段候選藥物。
The analyst writes that the FDA considered lead program INO-3107 Phase 1/2 clinical trials sufficient for the Accelerated Approval Program.
該分析師寫道，美國食品藥品管理局認爲牽頭項目 INO-3107 1/2 期臨床試驗足以完成加速批准計劃。
If approved, INO-3107 could be the first non-surgical treatment for recurrent respiratory papillomatosis (RRP).
如果獲得批准，INO-3107 可能成爲複發性呼吸道乳頭狀瘤病 (RRP) 的首種非手術治療方法。
RRP is a rare chronic disease caused by the human papillomavirus. In RRP, wart-like tumors grow on and around vocal cords.
RRP 是一種罕見的慢性病，由人乳頭瘤病毒引起。在 RRP 中，疣狀腫瘤生長在聲帶上和周圍。
FDA marketing application submission for INO-3107 is on track for the second half of 2024.
美國食品藥品管理局按計劃在 2024 年下半年提交 INO-3107 的上市申請。
The analyst initiated coverage with an Overweight rating with a price target of $20.
該分析師以增持評級啓動了報道，目標股價爲20美元。
Stephens says INOVIO's proprietary technology and approach involves developing and administering DNA plasmids into affected cells to restore normal functionality.
斯蒂芬斯說，INOVIO的專有技術和方法涉及開發DNA質粒並將其注射到受影響的細胞中，以恢復正常功能。
The DNA Medicines pipeline also has early clinical stage programs ongoing for head and neck squamous cell carcinoma, glioblastoma, and as an Ebola vaccine booster.
DNA Medicines產品線中還正在進行鍼對頭頸部鱗狀細胞癌、膠質母細胞瘤以及作爲埃博拉疫苗助推器的早期臨床階段項目。
"We view the efficiencies implemented by the leadership team will translate over to more "high-percentage shots-on-goal" to de-risk the platform technology," Stephens writes.
斯蒂芬斯寫道：“我們認爲，領導團隊實施的效率將轉化爲更高的 “高射門率”，從而降低平台技術的風險。”
The analyst also writes, "New leadership and strategic reorganizations align focus to lead programs and operational efficiencies."
該分析師還寫道：“新的領導層和戰略重組使重點與領導項目和運營效率保持一致。”
Price Action: INO shares are up 2.55% at $11.65 at last check Tuesday.
價格走勢：在週二的最後一次檢查中，INO股價上漲2.55％，至11.65美元。
譯文內容由第三人軟體翻譯。